Performance evaluation of the bio-rad BioPlex 2200 multiplex system in the detection of measles, mumps, rubella, and varicella-zoster antibodies

IF 1.6 Q4 INFECTIOUS DISEASES Journal of clinical virology plus Pub Date : 2023-02-01 DOI:10.1016/j.jcvp.2022.100131

Matthew A. Lafrenière , Eley Badr , John Beattie , Joseph Macri , Waliul I. Khan

{"title":"Performance evaluation of the bio-rad BioPlex 2200 multiplex system in the detection of measles, mumps, rubella, and varicella-zoster antibodies","authors":"Matthew A. Lafrenière , Eley Badr , John Beattie , Joseph Macri , Waliul I. Khan","doi":"10.1016/j.jcvp.2022.100131","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Measles, mumps, rubella, and varicella-zoster (MMRV) immunity testing is important in occupational screening of healthcare workers and at-risk populations.</p></div><div><h3>Objectives</h3><p>The goal of this study was to compare the performance of the Bio-Rad BioPlex 2200 MMRV multiplex fluorescence immunoassay (MFI) against two enzyme immunoassay (EIA) methods: the Bio-Rad Evolis Twin Plus measles, mumps, and varicella-zoster (MMV) IgG assay and the Abbott Architect Rubella IgG assay.</p></div><div><h3>Study Design</h3><p>Clinically uncharacterized serum specimens were obtained and analyzed using the Bio-Rad BioPlex assay and compared against the EIA methods.</p></div><div><h3>Results</h3><p>The Bio-Rad BioPlex demonstrated total agreement of 85.5% (95% confidence interval (CI), 78.0 to 90.7%), 92.7% (95% confidence interval (CI), 86.7 to 96.1%), 92.4% (95% confidence interval (CI), 86.9 to 95.7%), and 98.8% (95% confidence interval (CI), 93.7 to 99.8%) for measles, mumps, varicella-zoster, and rubella, respectively, against the current EIA methods. Furthermore, precision testing agreed with the manufacturer's package insert in 10 of 13 pooled samples.</p></div><div><h3>Conclusion</h3><p>These data indicate that the Bio-Rad BioPlex has comparable performance to the EIA methods.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 1","pages":"Article 100131"},"PeriodicalIF":1.6000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038022000709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Measles, mumps, rubella, and varicella-zoster (MMRV) immunity testing is important in occupational screening of healthcare workers and at-risk populations.

Objectives

The goal of this study was to compare the performance of the Bio-Rad BioPlex 2200 MMRV multiplex fluorescence immunoassay (MFI) against two enzyme immunoassay (EIA) methods: the Bio-Rad Evolis Twin Plus measles, mumps, and varicella-zoster (MMV) IgG assay and the Abbott Architect Rubella IgG assay.

Study Design

Clinically uncharacterized serum specimens were obtained and analyzed using the Bio-Rad BioPlex assay and compared against the EIA methods.

Results

The Bio-Rad BioPlex demonstrated total agreement of 85.5% (95% confidence interval (CI), 78.0 to 90.7%), 92.7% (95% confidence interval (CI), 86.7 to 96.1%), 92.4% (95% confidence interval (CI), 86.9 to 95.7%), and 98.8% (95% confidence interval (CI), 93.7 to 99.8%) for measles, mumps, varicella-zoster, and rubella, respectively, against the current EIA methods. Furthermore, precision testing agreed with the manufacturer's package insert in 10 of 13 pooled samples.

Conclusion

These data indicate that the Bio-Rad BioPlex has comparable performance to the EIA methods.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Bio-Rad BioPlex 2200复合系统检测麻疹、腮腺炎、风疹和水痘带状疱疹抗体的性能评价

背景麻疹、腮腺炎、风疹和水痘-带状疱疹（MMRV）免疫测试在医护人员和高危人群的职业筛查中很重要。目的本研究的目的是比较Bio-Rad BioPlex 2200 MMRV多重荧光免疫测定（MFI）与两种酶免疫测定（EIA）方法的性能：Bio-Rad Evolis Twin Plus麻疹、腮腺炎和水痘带状疱疹（MMV）IgG测定和Abbott Architect Rubella IgG测定。研究设计使用Bio-Rad-BioPlex测定法获得并分析临床上未表征的血清样本，并与EIA方法进行比较。结果Bio-Rad-BioPlex对麻疹、腮腺炎、水痘-带状疱疹和风疹的总符合率分别为85.5%（95%置信区间，78.0至90.7%）、92.7%（95%可信区间，86.7至96.1%）、92.4%（95%置信间隔，86.9至95.7%）和98.8%（95%置信程度，93.7至99.8%）。此外，在13个合并样本中的10个样本中，精密度测试与制造商的包装插入物一致。结论这些数据表明，Bio-Rad-BioPlex具有与EIA方法相当的性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊